双价与四价HPV疫苗对非疫苗高危型中和抗体应答的系统综述
结果显示双价疫苗对非疫苗高危型免疫应答高于基线或四价疫苗,九价疫苗对HPV 31、33、45、52、58几乎完全血清阳转且至首剂后24个月仍接近100%,而双价和四价对非疫苗型血清阳转率较低且随时间衰减;作者认为交叉保护应答无法与型特异性应答相比,超过两年的长期数据有限且检测方法缺乏标准限制可比性。
要点
- 双价疫苗对非疫苗高危型免疫应答高于基线或四价疫苗。
- 九价疫苗对HPV 31、33、45、52、58血清阳转近完全,24个月仍近100%。
- 双价和四价对非疫苗型血清阳转较低且随时间衰减。
核心结论
- 完成三剂双价或四价疫苗者的交叉保护抗体/免疫应答无法与疫苗型别特异性应答相比。
- 即使报告有统计学显著交叉反应免疫应答,超过两年的长期持续时间数据非常有限。
- 检测方法缺乏标准限制了研究间结果的可比性。
研究设计与样本
- 系统文献综述,检索PubMed和EMBASE数据库2008至2019年文献。
- 关键结局为针对HPV 6、11、31、33、45、52、58的血清阳转、血清阳性或几何平均滴度。
主要发现
- 双价疫苗接种后对非疫苗高危HPV型的免疫应答高于基线或四价疫苗。
- 九价疫苗对HPV 31、33、45、52、58引发接近完全的血清阳转,首剂后24个月血清阳性率仍接近100%。
- 双价和四价疫苗对非疫苗型别血清阳转水平较低,且随时间衰减。
临床怎么用
- 解读双价或四价HPV疫苗交叉保护数据时,应认识到其非疫苗型应答低于九价疫苗的型特异性应答。
- 评估交叉保护持久性时需注意现有长期数据不超过两年且检测方法不统一。
局限性
- 超过两年的交叉反应免疫应答长期数据非常有限。
- 检测方法缺乏标准,限制研究间结果可比性。
- 纳入研究包含干预性与观察性设计,异质性可能影响汇总解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Studies on the cross-protective effect of HPV bivalent and quadrivalent vaccines demonstrated inconsistent findings against additional HPV types covered by the nonavalent vaccine. The objective of this study was to conduct a systematic literature review to assess the consistency and durability of the cross-protective neutralizing antibody immune responses of the currently licensed bivalent and quadrivalent vaccines to non-vaccine HPV types targeted by the nonavalent vaccine (HPV 6, 11, 31, 33, 45, 52, and 58). METHODS: PubMed and EMBASE databases were searched from 2008 to 2019 to identify studies reporting antibody/immune response after vaccination with either the bivalent, quadrivalent, or nonavalent vaccine. Key outcomes were seroconversion, seropositivity or geometric mean titers against HPV types 6, 11, 31, 33, 45, 52, and 58. RESULTS: Eighteen publications met inclusion criteria, reporting on 14 interventional and five observational studies. Across all studies, immune responses to non-vaccine high-risk HPV types after bivalent vaccination were higher than baseline or quadrivalent vaccine. Nonavalent vaccine elicited near total seroconversion to HPV types 31, 33, 45, 52, and 58, with seropositivity remaining near 100% up to 24 months post-dose 1. In contrast, bivalent and quadrivalent vaccination resulted in lower seroconversion levels for non-vaccine types, which waned over time. CONCLUSIONS: The cross-protection antibody/immune response among participants having received all three doses of bivalent or quadrivalent vaccine is not comparable to the specific response elicited by HPV vaccine types. Even in cases where a statistically significant cross-reactive immunological response is reported, long-term data on the duration of the response beyond two years are very limited. Further, the lack of a standard for assays limits comparability of results between studies.
引用
- Stanley M, Joura E, Yen GP, et al. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. Vaccine. 2021. PMID: 33658126. doi:10.1016/j.vaccine.2021.01.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。